Lognevity drugs might not cost a fortune

At the World Science Festival, Harvard University professor and co-founder of Sirtris Pharmaceuticals talked about a molecule that targets a gene linked to longevity at a discussion on the science of longevity.  Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.